TipRanks (Tue, 1-Sep 8:35 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Mon, 31-Aug 8:50 AM ET)
TELA Bio Implements Workforce Cuts and Leadership Changes
TipRanks (Mon, 31-Aug 7:28 AM ET)
TELA Bio COO/CFO Roberto Cuca steps down
Seeking Alpha News (Mon, 31-Aug 7:21 AM ET)
TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative
Globe Newswire (Mon, 31-Aug 7:00 AM ET)
TELA Bio Reports Second Quarter 2026 Financial Results
Globe Newswire (Mon, 10-Aug 4:05 PM ET)
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Wed, 5-Aug 4:05 PM ET)
TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director
Globe Newswire (Tue, 4-Aug 7:00 AM ET)
TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
Globe Newswire (Wed, 29-Jul 4:05 PM ET)
TELA Bio to Announce Second Quarter 2026 Financial Results
Globe Newswire (Mon, 20-Jul 4:05 PM ET)
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
Tela Bio trades on the NASDAQ stock market under the symbol TELA.
As of September 2, 2026, TELA stock price declined to $0.75 with 129,061 million shares trading.
TELA has a beta of 1.93, meaning it tends to be more sensitive to market movements. TELA has a correlation of 0.08 to the broad based SPY ETF.
TELA has a market cap of $33.78 million. This is considered a Sub-Micro Cap stock.
Last quarter Tela Bio reported $19 million in Revenue and -$.20 earnings per share. This fell short of revenue expectation by $-715,720 and missed earnings estimates by -$.02.
In the last 3 years, TELA traded as high as $9.60 and as low as $.50.
The top ETF exchange traded funds that TELA belongs to (by Net Assets): VTI, VXF.
TELA has underperformed the market in the last year with a return of -57.7%, while the SPY ETF gained +19.8%. In the last 3 month period, TELA fell short of the market, returning -16.4%, while SPY returned +1.1%. However, in the most recent 2 weeks TELA has outperformed the stock market by returning +17.0%, while SPY returned -0.3%.
TELA support price is $.72 and resistance is $.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TELA shares will trade within this expected range on the day.
